The estimated Net Worth of Martha J. Carter is at least $1.95 Миллион dollars as of 23 January 2023. Ms. Carter owns over 120 units of Albireo Pharma Inc stock worth over $640,440 and over the last 8 years she sold ALBO stock worth over $64,849. In addition, she makes $1,243,480 as Chief Regulatory Officer at Albireo Pharma Inc.
Sign up
Ms. Carter ALBO stock SEC Form 4 insiders trading
Martha has made over 8 trades of the Albireo Pharma Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently she sold 120 units of ALBO stock worth $5,256 on 23 January 2023.
The largest trade she's ever made was exercising 30,000 units of Albireo Pharma Inc stock on 8 September 2020 worth over $636,600. On average, Martha trades about 2,322 units every 48 days since 2016. As of 23 January 2023 she still owns at least 14,506 units of Albireo Pharma Inc stock.
You can see the complete history of Ms. Carter stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Martha Carter biography
Martha J. Carter is the Chief Regulatory Officer of Albireo Pharma Inc. She previously served as Chief Regulatory Officer and Senior Vice President of Aegerion Pharmaceuticals, Inc. (a publicly held biopharmaceutical company) from February 2011 to July 2016. From January 2011 to February 2011, Ms. Carter served as Senior Vice President and Chief Regulatory Officer at Proteon Therapeutics, Inc. (a privately held biopharmaceutical company), and from September 2006 to December 2010, she served as Senior Vice President, Regulatory Affairs and Quality Assurance, at Proteon. From September 2002 to April 2006, Ms. Carter was Senior Vice President, Regulatory Affairs, for Trine Pharmaceuticals. Prior to joining Trine, Ms. Carter was Vice President, Regulatory Affairs for GelTex Pharmaceuticals, Inc. and served in regulatory affairs roles at Genetics Institute, ImmuLogic Pharmaceutical Corporation and Serono Laboratories. Ms. Carter holds a B.A. from Northeastern University.
What is the salary of Martha Carter?
As the Chief Regulatory Officer of Albireo Pharma Inc, the total compensation of Martha Carter at Albireo Pharma Inc is $1,243,480. There are 3 executives at Albireo Pharma Inc getting paid more, with Ronald Cooper having the highest compensation of $2,995,410.
How old is Martha Carter?
Martha Carter is 67, she's been the Chief Regulatory Officer of Albireo Pharma Inc since 2016. There are 3 older and 17 younger executives at Albireo Pharma Inc. The oldest executive at Albireo Pharma Inc is Davey Scoon, 73, who is the Independent Director.
What's Martha Carter's mailing address?
Martha's mailing address filed with the SEC is C/O ALBIREO PHARMA, INC., 53 STATE STREET, 19TH FLOOR, BOSTON, MA, 02109.
Insiders trading at Albireo Pharma Inc
Over the last 8 years, insiders at Albireo Pharma Inc have traded over $26,339,822 worth of Albireo Pharma Inc stock and bought 932,623 units worth $30,497,757 . The most active insiders traders include Advisors Llcperceptive Life..., Roger Jeffs и Plcastrazeneca Ab Astrazeneca. On average, Albireo Pharma Inc executives and independent directors trade stock every 19 days with the average trade being worth of $957,260. The most recent stock trade was executed by Pamela Stephenson on 23 January 2023, trading 102 units of ALBO stock currently worth $4,468.
What does Albireo Pharma Inc do?
Albireo Pharma is a clinical-stage biopharmaceutical company focused on the development of novel bile acid modulators to treat rare pediatric and adult liver diseases, and other adult liver diseases and disorders. Albireo's lead product candidate, odevixibat, is being developed to treat rare pediatric cholestatic liver diseases with Phase 3 pivotal trials in PFIC, Alagille syndrome and biliary atresia. The Company completed IND-enabling studies for new preclinical candidate A3907 this year and plans to advance development in adult liver disease. Albireo was spun out from AstraZeneca in 2008 and is headquartered in Boston, Massachusetts, with its key operating subsidiary in Gothenburg, Sweden. The Boston Business Journal named Albireo one of the 2020 Best Places to Work in Massachusetts for the second consecutive year.
What does Albireo Pharma Inc's logo look like?
Complete history of Ms. Carter stock trades at Albireo Pharma Inc
Albireo Pharma Inc executives and stock owners
Albireo Pharma Inc executives and other stock owners filed with the SEC include:
-
Ronald Cooper,
President, Chief Executive Officer, Director -
Pamela Stephenson,
Chief Commercial Officer -
Jan Mattsson,
Chief Scientific Officer -
Martha Carter,
Chief Regulatory Officer -
Ronald H. W. Cooper,
CEO, Pres & Director -
Patrick Horn,
Chief Medical Officer -
Martha J. Carter,
Chief Regulatory Officer -
Simon Nicolas Reade Harford,
CFO & Treasurer -
David Chiswell,
Independent Chairman of the Board -
Davey Scoon,
Independent Director -
Michael Gutch,
Independent Director -
Roger Jeffs,
Independent Director -
Stephanie Okey,
Independent Director -
Anne Klibanski,
Independent Director -
Jason Duncan,
Chief Legal Officer, General Counsel, Secretary -
Michelle Graham,
Chief Human Resource Officer -
Simon Harford,
Chief Financial Officer, Treasurer -
Jason G. Duncan,
Chief Legal Officer, Gen. Counsel & Sec. -
Pamela Stephenson M.P.H.,
Chief Commercial Officer -
Dr. Kristina Torfgard,
VP & Global Project Head -
Michelle Graham,
Chief HR Officer -
Joan Connolly,
Chief Technology Officer -
Dr. Jan P. Mattsson Ph.D.,
Chief Scientific Officer, MD (Sweden) & Co-Founder -
Dr. Per-Goran Gillberg,
Co-Founder & VP of Devel. -
Denise Scots Knight,
Director -
Julia R Brown,
Director -
Heather Preston,
Director -
Paresh Soni,
Chief Medical Officer -
Thomas A. Shea,
CFO and Treasurer -
Peter A Zorn,
Senior VP, Corp Dev, GC & Sec -
Plcastrazeneca Ab Astrazeneca,
-
Paul Streck,
Chief Medical Officer -
Advisors Llcperceptive Life...,
-
Partners Ltd Phase4 Venture...,
-
Craig C. Hopkinson,
Director -
Susan Alesina,
Director -
Habib J Dable,
Director